KLF4 overexpression in CAR T cells enhances antitumor potency by preventing exhaustion.

Notably, KLF4-overexpressing CAR T cells delayed tumor growth, prolonged the survival of mice with hematological malignancies, and exhibited reduced exhaustion and enhanced effector functions in vivo relative to normal CAR T cells. The findings highlight the potential of KLF4 overexpression as a therapeutic approach to counteract CAR T-cell exhaustion and enhance antitumor activity, underscoring its therapeutic promise in clinical immunotherapy.

For PBMC suspensions, Countstar (model not specified) provided cell-count measurements during quality assessment in the 2026 Journal for immunotherapy of cancer study.